FindTrial
Sign In

SyB L-0501

DRUG6 trials

Sponsors

SymBio Pharmaceuticals

Conditions

Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaDiffuse, Mantle Cell Lymphoma, LymphomaFollicular LymphomaLarge B-Cell, DiffuseLow-grade B Cell Non-Hodgkin's LymphomaLymphoma, Large CellMantle Cell Lymphoma

Phase 1

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
CompletedNCT00794638
SymBio PharmaceuticalsDiffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma +1
Start: 2008-11-30End: 2010-05-31Updated: 2021-07-02

Phase 2

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
CompletedNCT01118845
SymBio PharmaceuticalsDiffuse, Mantle Cell Lymphoma, Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse +2
Start: 2010-04-30End: 2011-10-31Updated: 2013-07-04
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
TerminatedNCT01179490
SymBio PharmaceuticalsMultiple Myeloma
Start: 2010-09-30Updated: 2013-03-18
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
CompletedNCT01718691
SymBio PharmaceuticalsLow-grade B Cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Start: 2011-11-30End: 2013-11-30Updated: 2016-04-27
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
CompletedNCT01849848
SymBio PharmaceuticalsRelapsed/Refractory Multiple Myeloma
Start: 2011-11-30End: 2013-07-31Updated: 2015-02-06
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
CompletedNCT02042911
SymBio PharmaceuticalsChronic Lymphocytic Leukemia
Start: 2013-01-31End: 2015-06-30Updated: 2017-02-01

Related Papers

Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.
Journal of Clinical Oncology2016-05-20